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Abstract
Background: Precursors to anal squamous cell carcinoma may be detectable through screening; however, the
literature suggests that population-level testing is not cost-effective. Given that high-grade cervical neoplasia (CIN)
is associated with an increased risk of developing anal cancer, and in light of changing guidelines for the follow-up
and management of cervical neoplasia, it is worthwhile to examine the costs and effectiveness of an anal cancer
screening program delivered to women with previously-detected CIN.
Methods: A model of anal cancer screening and treatment was constructed, to estimate the cost-effectiveness of a
population of CIN II/III+ women who were screened using anal cytology vs. one that received no anal cancer
screening. Costs were based on Canadian estimates, and survival was based on estimates taken from the scientific
literature. Effectiveness was measured in terms of life years gained (LYG) and quality-adjusted life years (QALYs). The
model was run for 50 cycles, with each cycle representing one year.
Results: Incremental cost (screened vs. unscreened) was $82.17 per woman in the model. Incremental effectiveness
was 0.004 LYG, and was equivalent to zero in terms of QALY. An ICER of $20,561/LYG was calculated, while no
meaningful incremental cost-effectiveness ratio (ICER) could be calculated for quality-adjusted survival.
Conclusion: Our analysis suggests that anal cancer screening is cost-effective in terms of overall survival in women
with a previous diagnosis of CIN II or CIN III as part of regular follow-up, but may not contribute meaningfully-different
quality-adjusted survival due to the adverse effects of screening-related interventions.
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Background
Squamous cell carcinoma (SCC) of the anal canal is a
relatively rare cancer of the gastro-intestinal (GI) tract,
representing approximately 1.5 % of GI cancers [1].
Several risk factors for anal SCC (ASCC) and its pre-
cursor lesions low-grade squamous anal intraepithelial
neoplasia (AIN1) and high-grade squamous anal intrae-
pithelial neoplasia (AIN2+) have been identified including
high-risk Human Papillomavirus (HPV) infection, Human
Immunodeficiency Virus (HIV) infection, immunosup-
pression, and men who have sex with men (MSM) [2]. In
women it is well established that Cervical Intraepithelial
Neoplasia (CIN), often detected through cervical cancer
screening, is linked to high-risk HPV subtypes and pro-
gression to invasive cervical cancer if left untreated [2–4]
and multiple studies have shown that women with a past
diagnosis of CIN or cervical cancer are also at increased
risk of developing anal cancer [5–9]. It has also been
shown that women with CIN have a much higher rate of
AIN1 and AIN2+ than the general population, likely
because of concurrent HPV infections of the cervical and
anal mucosae [10–15].
Given that AIN1 and AIN2+ may have a lag time as long
as 5–10 years (or more) [16, 17] before progressing to
ASCC, early detection of pre-cancers through screening
may be an effective way of reducing cancer incidence and
burden. Anal cancer screening strategies have predomin-
antly been applied to high-risk populations, mainly HIV
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positive MSM, but the scientific literature is not clear on
the cost-effectiveness of such programs. Goldie et al. found
that anal cancer screening is cost-effective in HIV positive
MSM; the cost per quality-adjusted life year (QALY) is
approximately $16,600 [18]. However, research by an NHS
committee led by Czoski-Murray et al. [3, 19] and the
Medical Advisory Secretariat from Ontario Canada [20],
specifically mandated to look at cost-effectiveness of
screening for ASCC, contested this finding. Both teams
concluded that no subgroup, be it men or women, status
HIV positive or negative, stood to benefit from anal cancer
screening [3, 20]. Lazenby et al. have recently challenged
this view for high-risk HIV positive women, claiming that
anal cancer screening would be cost-effective in women
with CD4 counts of less than 200 [21].
Despite the lack of clear consensus in the medical litera-
ture, many jurisdictions such as clinics in San Francisco
and Vancouver have adopted anal cancer screening pro-
grams for HIV positive MSM and are evaluating the possi-
bility of widening indications for screening to other risk
groups such as HIV negative MSM, and women at high
risk such as HIV positive women and women with a his-
tory of cervical dysplasia. These women’s risk of AIN is
thought to be approximately threefold that of the normal
population [11]. HIV+ women were found to have a 12 %
prevalence of AIN which is similar to that of women with
CIN [11]. Santoso et al. found a very similar prevalence
rate of AIN at 12 % in women with CIN [13].
Because of the desire for these programs, and the
changing international guidelines for the management of
CIN [22, 23], this is a valuable time to examine the pos-
sibility of creating an anal cancer screening program in
this population, and to explore whether or not such a
program could be delivered in a cost-effective way. To
our knowledge, no cost-effectiveness evaluations of an
anal cancer screening program have been published con-
cerning women with a past diagnosis of CIN, who could
be considered a high-risk group.
For this reason, this study’s objective was to design a
model to estimate the cost-effectiveness of adding anal
cancer screening to ordinary follow-up for women with
a past diagnosis of CIN.
Methods
This population was selected because it is comprised of
people who already participate in regular screening. The
intervention proposed in the model is the addition of anal
screening to the current follow-up schedule, rather than
the creation of a new parallel screening program.
A cost-effectiveness analysis was conducted using a
Markov health state transition model of anal cancer
screening and treatment. A schematic of the model is
provided in Fig. 1. The model, programmed in the R en-
vironment (R Foundation for Statistical Computing,
Austria), was run for 50 cycles, with each cycle represent-
ing 1 year (i.e., the model’s rull run represents 50 years of
time). Each arm of the model simulated 10,000 women.
Health state transition model
In the “Screened” arm of the model, women with a
previously-detected CIN II or CIN III dysplasia are
screened for AIN1 or AIN2+ via anal cytology testing. True
negatives (i.e., no AIN1 or AIN2+, negative finding on
screen) begin in the “Post-screen Negative” health state.
False negatives (i.e., positive AIN1 or AIN2+ status, nega-
tive finding on screen) begin in the “Undetected AIN1” or
“Undetected AIN2+” health states. Screen-positive women
are then evaluated with high-resolution anoscopy. True
positive AIN1 or AIN2+ (i.e., positive cytology status,
positive finding on anoscopy) is managed via resection in
the model (despite lack of consensus, the only option
included in the model was resection rather than office-
based resection as resection is assumed to be the more
costly of the two). Women with successfully-resected
dysplasia begin the model in the “Post-resection Negative”
health state, and receive re-screening on the same sched-
ule as healthy women. Women with dysplasia that is not
successfully resected begin in the “Undetected AIN1” or
“Undetected AIN” health states, depending on their
cytology status. Women with false positive findings (i.e.,
negative cytology status, positive finding on screen, nega-
tive finding on anoscopy) begin the model in the “Post-
screen Negative” state.
The anal screening process repeats for all women in
year two and once again in year five. Follow-up screen-
ing occurs once every 3 years until year 20, after which
time screening stops. The screening schedule in the
model resembles screening strategies suggested by most
recent international guidelines [22, 23]. This process is
described in Fig. 1a.
In the “Unscreened” arm of the model, all cases of AIN1
and AIN2+ are undetected (see Fig. 1b).
Cytology-negative women (in either arm of the model)
may develop AIN1. AIN1 may resolve spontaneously or
progress to AIN2+. AIN2+ may progress to early-stage or
late-stage anal cancer (i.e., ASCC) or present as metastatic
disease.
The model assumes that ASCC cases are managed
according to British Columbia Cancer Agency (BCCA)
guidelines, with both early and late-stage localized
disease treated with chemoradiation therapy [24]; the
disease may respond to treatment (“Well, post-Tx”) or
not (“Non-responsive progressive disease”). Women with
progressive disease may die within the year – those who
survive may remain in the progressive disease health
state, or progress to metastatic disease. Women with
metastatic disease may die from cancer. The cancer sur-
vival phase of the model is presented in Fig. 1c.
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Costs
Costs to the Canadian health care system were based on
estimates published in British Columbian provincial
sources [24–26] and from the health economics literature
when BC-specific estimates were not available [19, 27]. All
cost parameters are described in Table 1. Costs were
expressed in 2014 Canadian dollars, adjusted for inflation
using the Consumer Price Index for health care produced
by Statistics Canada [28]. Discounting was applied to all
costs and outcomes at a rate of 5 % to account for future
time preference, as recommended by the Canadian
Agency for Drugs and Technologies in Health [29].
Transition probabilities
Transition probabilities represent the chance that
an individual will move from one health state to
another (or remain in that state) from one cycle to
the next. Transition probabilities are described in
Table 1, along with probabilities associated with
screening. These probabilities were derived from es-
timates in the health economic and clinical litera-
ture, and were chosen based on recency of
publication, size of population studied, and applic-
ability/appropriateness to the process being
modeled.
Fig. 1 Health State Transition Model Schematic. a Pre-symptomatic phase, Screening Arm; b Pre-Symptomatic phase, Comparator Arm; c Cancer
survival phase, Both Arms
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Table 1 Health State Transition Model Parameters
Parameter Point Estimate SE Distribution used in PSA Source
Transition probability
AIN Status
No AIN 88 % 3.2 % Dirichlet Santoso, 2010 [13]
AIN1 11 % 3.1 %
AIN2+ 1 % 1.0 %
Screening utility of Pap Santoso, 2010 [13]
Sensitivity 40 % 2.6 % Normal
Specificity 94 % 2.6 % Beta
Resection failure rate 10 % 1.0 % Normal Abbasakoor, 2005
AIN1 lesion recurrence rate 25 % 3.2 % Normal
AIN2+ lesion recurrence rate 25 % 3.1 % Normal
Pre-cancer survival Palefsky, 1998 [35]
Development of new AIN1 3.5 % 1.3 % Beta
Remission of AIN1 3.5 % 1.5 % Beta
Progression from AIN1 to AIN2+ 20 % 2.0 % Normal
Development of cancer Adapted from Malachek 2012 [36] for
HIV- MSM
AIN2+ to Early-stage ASCC 0.012 % 0.001 % Normal
AIN2+ to Late-stage ASCC 0.006 % 0.001 % Normal
AIN2+ to Metastatic ASCC 0.002 % 0.0004 % Normal
Cancer survival AJCC 2010 [2, 37]
Uronis 2007
Progressive disease following early-stage treatment 20 % 2.5 % Normal
Progressive disease following late-stage treatment 50 % 4.1 % Normal
Recurrence 15 % 1.2 % Normal
Progression to metastatic disease 50 % 2.2 % Normal
Death from progressive disease 80 % 4.1 % Beta
Death from metastatic disease 100 % 0.5 % Beta
Health utilities˧
No AIN 0.98 0.028 Beta Insinga, 2007 [38] ǂ
Undetected AIN1 0.98 0.024 Beta Insinga, 2007 [38]
Undetected AIN2+ 0·98 0.024 Beta Insinga, 2007 [38]
Screen-detected lesion, resection 0·87 0.085 Beta Insinga, 2007 [38]
Successfully-managed ASCC
First year 0·57 0.020 Normal Conway, 2012 [39]
Subsequent years 0·82 0.068 Beta Melnikow, 2010 [40] ǂ
Progressive ASCC 0.57 0.020 Normal Conway, 2012 [39]
Metastatic ASCC 0.57 0.020 Normal Conway, 2012 [39]
Costs
Cost of anal swab $6 $6 Gamma BC Cancer Agency
Cost of anoscopy $7.55 $7.55 Gamma BC Ministry of Health
Cost of resecting an anal lesion $73.96 $73.96 Gamma BC Ministry of Health
Cost of a screening appointment $30.15 $30.15 Gamma BC Ministry of Health
Cromwell et al. BMC Health Services Research  (2016) 16:206 Page 4 of 10
Quality of life (QoL)
Estimates for health state utility weights following
screening and during the management of anal cancer are
described in Table 1. Utilities for cervical cancer were
substituted when anal cancer-specific utilities were not
available.
Cost-effectiveness analysis
The difference in total survival experienced by women
in either arm of the model was calculated as Life Years
Gained (LYG). Quality-weighted incremental survival
was also calculated as Quality-Adjusted Life Years
gained (QALYs). Incremental Cost-Effectiveness ratios
(ICERs) were calculated for incremental cost per LYG
and cost per QALY.
To account for the effect of uncertainty around param-
eter estimates, Probabilistic Sensitivity Analysis (PSA) was
performed via Monte Carlo simulation [30]. Univariate
Sensitivity Analysis (SA) was performed on each model
parameter to investigate the extent to which incremental
costs and effectiveness is changed by variations in the
value of each model input. Model parameters were ad-
justed to 50 and 150 % of their baseline value to estimate
the extent to which the ICER is sensitive to changes in
each input – proportions and utilities lying close to 1.0
were adjusted by 0.1 (or less, in the case of Pap sensitivity)
to reflect the underlying distribution of values.
Estimated value of partial perfect information
The estimated value of partial perfect information
(EVPPI) is a measure describing the degree to which a
reduction in the uncertainty around an individual model
parameter will result in a more cost-effective decision.
For a given willingness to pay (WTP) for an additional
year of life, it is somewhat likely that adoption of a new
policy or technology (in this case, the addition of anal
cancer screening to CIN II/III follow-up) will not be
cost-effective due to the level of uncertainty around one
or more model values. Since decisions are made on a
“yes/no” basis, there is a chance that, because of param-
eter uncertainty, we may make a different decision than
if we knew the value of the parameter with absolute
certainty.
EVPPI analysis estimates the effect on the Net Benefit
(incremental costs minus the value of incremental bene-
fits, either in LYG or QALY) if we had ‘perfect’ informa-
tion (i.e., zero uncertainty about the value of a given
parameter), expressed as the per-person dollar value we
might gain by not making a non-cost-effective decision.
EVPPI was calculated using a validated R script written
by Sadatsafavi et al. [31].
Results
The incremental cost of the screened arm compared to
the unscreened arm was $82.17 per woman. A survival
difference of 4.34 × 10−3 (0.00434) LYG was found – this
value is statistically distinct from zero. The resulting
ICER was $20,562/LYG. A mean value of −0.0364 QALY
was found (i.e., more quality-adjusted survival was observed
in the unscreened arm), suggesting that an unscreened
population has preferable quality-adjusted survival when
compared to one that is screened. It must be noted, how-
ever, that this result is not statistically distinct from zero
QALY (see Fig. 2).
PSA strongly suggests a great deal of uncertainty
around quality-adjusted outcomes – incremental QALY
estimates were greater than zero nearly as often as they
were smaller than zero. The reduction in QoL associated
with screening, primarily resection of low- and high-
grade dysplasia, is greater than the avoided QoL loss that
accompanies the reduction in cancer frequency. While
the disutility for cancer is much higher, cancer is still a
very rare outcome, even in this population. As a result,
incremental QALYs are near (or slightly below) zero.
The change in screening policy resulted in a reduction
of 7.59 cases of anal cancer per 100,000 population per
year, at a cost-per-avoided-cancer of $65,403.
Cost-effectiveness acceptability curves are shown in
Fig. 3. These curves represent the proportion of model
ICERs that lie below a given ‘threshold’ value that a
decision-making authority would be willing to pay for a
LYG or QALY. Our findings suggest that screening
becomes cost-effective at a willingness-to-pay (WTP)
threshold of $45,500/LYG (5 % significance level). There
is no threshold at which cost/QALY reaches cost-
effective at that significance level, as roughly half of
Table 1 Health State Transition Model Parameters (Continued)
Cost of treating ASCC $11,625 $11,625 Gamma BCCA Ŧ
Cost of cancer follow-up appointment $464 $46 Gamma Tsoi, 2010 [27]
Cost of managing progressive ASCC $18,377 $3634 Normal Czoski-Murray, 2010 [19]
Cost of managing metastatic disease $36,612 $7288 Normal Tsoi, 2010 [27]
ASCC anal squamous cell carcinoma, AIN anal interepithelial neoplasia, AIN1/AIN2+ low-grade/high-grade AIN, CIN cervical interepithelial neoplasia
˧ N.B. Utilities are assumed to be constant over the value of a cycle length (i.e., 1 year)
ǂ N.B. Because anal screening utility weights were not available, utilities were assumed to be similar to values found in women screened and treated for
cervical lesions/cancers
Ŧ Based on cost of BCCA Chemoradiation protocols GIPART, GICART [26] – drug and administration costing data provided by BCCA Systemic Therapy Program
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probable ICERs lay to the left of the Y axis (i.e., screen-
ing was dominated).
Alternative screening scenarios
A scenario was tested wherein women are screened for
anal lesions once a year for the first 5 years after entering
the model (i.e., at year zero when a CIN II/III lesion is
detected – “one-off screening”). A second scenario
modeled a policy where women are screened with anal
cytology during their first year of follow-up only. Selected
results from these alternative scenarios are presented in
Table 2. The analysis suggests that, although reducing the
frequency and/or intensity of screening lowers incremen-
tal cost, incremental effectiveness is also lower.
Univariate sensitivity analysis
Selected results of this process are presented in Fig. 4.
Changes in the time horizon and the discounting rate for
outcomes strongly influenced the mean ICER. The model
is also sensitive to the effectiveness and cost of Pap
smears, as well as the incidence rate for anal cancer. A full
description of the univariate sensitivity results are avail-
able in Additional file 1 attached to this manuscript.
The QALY calculation was highly sensitive to changes
in utility weights for undetected AIN1 and AIN2+
(not shown) – incremental QALY adopted a positive
value (i.e., was no longer dominated by a strategy
with no screening) when utility weight was dropped

























Fig. 2 Incremental Cost-Effectiveness Plane for 10,000 Bootstrapped ICERs. a Cost/Life Year Gained (LYG); b Cost/quality-adjusted life year (QALY)
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Estimated value of partial perfect information
As suggested by the univariate SA, EVPPI analysis
returned a threshold of zero for most model parameters
(i.e., perfect information for the parameter would not re-
sult in a different decision) with a WTP threshold of
$50,000/LYG. The cost of Pap testing returned an EVPPI
of $0.48, and the true positive rate for screening
returned an EVPPI of $0.05. This finding suggests that,
although there is uncertainty around model parameter
estimates, reducing this parameter uncertainty is not
likely to change the decision about whether to adopt this
as part of routine screening.
EVPPI was calculated for incremental quality-adjusted
survival using a WTP threshold of $50,000/QALY. Based
on the output of the algorithm, a value of $475.44 was
found for the quality of life associated with having un-
detected AIN2+, suggesting that perfect information
about patient quality of life may be valuable in determin-
ing whether screening is truly cost-effective in terms of
quality-adjusted survival.
Discussion
We have created a model to generate health economic evi-
dence for whether a high-risk subpopulation – women with
CIN II/III lesions – should also be screened for anal lesions.
Based on the output of the model, screening CIN II/III
positive women for anal cancer appears to be cost-effective
in terms of overall survival, but was not different in terms
of quality-adjusted survival. It is beyond the scope of this
research to decide which measure – LYG or QALYs – is
the ‘correct’ one to use; however, it is worth noting that the
ostensible purpose of screening is to reduce the incidence
of disease. It is up to policy-makers to determine which
measure best reflects the priorities of their jurisdiction.
The model was sensitive to the time horizon and the
outcomes discount rate. Since screening occurs only in
the first 20 cycles (i.e., over the first 20 years following
detecting of CIN II/III), survival and costs in both the
screened and unscreened populations look increasingly
similar over time. As incremental survival approaches
zero, the size of the ICER increases. This suggests that
the cost-effectiveness of anal screening is higher in older
women than it is in younger women, but even among
young women the incremental cost is still very low.
We chose to model a scenario in which anal cancer
screening was conducted as part of an existing screening
program, rather than the creation of an entirely new
program. Given that a new screening program would be
more resource-intensive than adapting an existing pro-
gram, we feel that the scenario envisioned in this exer-
cise represents the most realistic method for introducing
anal cancer screening to the population. The specific
method examined in this model was designed based on
conversations with screening program leads in British
Columbia.
Fig. 3 Cost-Effectiveness Acceptability Curves for Anal Cancer
Screening. a Cost/Life Year Gained (LYG); b Cost/quality-adjusted life
year (QALY)
Table 2 Baseline and Alternative Screening Scenario Results
Scenario ΔCost LYG QALY Mean ICER Cost/Cancer avoided
Baseline $82.17 0.004 −0.0364 $20,561/LYG $67,933
Scenario A – 5 years of screening $68.25 0.002 −0.0195 $29,673/LYG; dominateda $148,532
Scenario B – “One-off” screening $13.06 0.0007 −0.0037 $52,602/LYG; dominateda $102,806
LYG – incremental Life Years Gained; QALY – incremental Quality-Adjusted Life Years; ICER – Incremental Cost-Effectiveness Ratio
athese ICERs should be interpreted as the function of a denominator that is centered around (or slightly below) zero, rather than the result of a cost reduction
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Our analysis relied on the assumption that women
after an anal screen experience similar quality of life to
women who have undergone a cervical screen – an
assumption that may not reflect the lived experience of
patients. For example, cervical screening may be more
normalized and therefore feel less invasive than anal
screening; or perhaps anxiety about anal cancer might
be greater than anxiety about cervical cancer. The accur-
acy of the model would likely be greatly improved by
utility estimates for people following screening for anal
cancer; however, these estimates are not readily available
from the scientific literature. Univariate SA and EVPPI
analyses suggest that the estimate of quality-adjusted
cost-effectiveness would be improved by more precise
information about health utility of people with untreated
AIN2+.
The model also assumes that a woman who has had a
resection for an anal lesion has a health disutility (loss of
utility) that is constant over the course of a year; however,
it is perhaps more likely that after the initial discomfort
associated with anoscopy and excision dissipates, women
return to a normal state of health earlier than 12 months.
If this is the case, screened women would likely have less
QoL reduction than our model estimates, resulting in a
more favourable incremental QALY estimate. By allowing
the QoL value to vary, our model accounts for the effect
of this uncertainty, albeit indirectly.
Our model suggests that while screening this popula-
tion for anal cancer may not lead to a large reduction in
mortality at the population level, the additional cost is
very low compared to other screening interventions that
see wider utilization [32].
Women with CIN II/III lesions are more likely to de-
velop cervical cancers than a sample drawn from the
general population. This risk has been estimated to be as
high as 1.6 % over 10 years and 12 % at 20 years [33],
with a risk of cervical cancer that is approximately six-
fold that of the general population [4]. The incidence
rate of invasive cervical cancer in women with CIN was
estimated to be 37 cases per 100,000 person-years in BC
women with CIN. This risk is substantially higher than
their risk of anal cancer which in BC women was esti-
mated to be approximately 3.6 cases per 100,000 person-
years (vs. an expected rate of 2 in the general population)
[34], but the risk of progression of AIN2+ to anal cancer
is thought to be 9–13 % over 10 years [16]. Seeing as their
risk of cervical cancer is much greater than that of anal
cancer, our model attempted to mirror their continued
screening for cervical cancer rather than add to it. Our
model does not include death by cervical cancer as a pos-
sible outcome, given that the risk of cervical cancer is
equal between the screened and unscreened arms. This
means that, although the model will likely overestimate
absolute costs and survival for a ‘real-world’ population of
screened women, the incremental costs and survival are
not likely to change (since an equal number of cervical
cancers can be expected in both screened and unscreened
women).
Our model also does not account for recurring CIN
II/III – it is possible that a woman’s cervical lesions return
following the original detection in year 0, which would
change the follow-up screening interval. A screening strat-
egy that includes the probability of CIN recurrence would
mean that the time horizon of screening would be longer
than 20 years, and the cost (and cancers avoided) would
increase as a result. We chose not to model this event, as
we felt it would greatly increase the complexity of the
model without adding much useful information – a fairly
small proportion of screened women with have a recur-
rent CIN II/III lesion, and will therefore contribute a com-
paratively small difference in costs and effectiveness that
is unlikely to affect the overall cost-effectiveness of adop-
tion. We feel that any difference due to recurrent CIN II/
III is likely accounted for in the sensitivity analysis, and
would likely not change the decision implication of
this study (i.e., screening would not likely become
non-cost-effective if CIN II/III recurrence was included in
the model).
For similar reasons of feasibility, we did not include
women with a history of cervical cancer, or who had
Fig. 4 Selected Results of Univariate Sensitivity Analysis. Baseline ICER = $20,562/LYG
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cervical cancer at the time of diagnosis. Treatment of co-
morbid cancers (i.e., cervical and anal cancer) is far more
complex than our model can simulate. Women with co-
morbid cancers will represent a very small percentage of
our target population, and their inclusion is unlikely to
strongly affect our estimates of cost-effectiveness.
Our model was limited by the availability of data to
inform transition probabilities and utilities. In order to
allow comparability between our exercise and the exist-
ing literature, we used on parameters and values from
previously-published studies. Because of the lack of
health utility estimates for anal cancer screening, we as-
sumed that utility values for AIN are similar to those for
CIN. Our sensitivity analysis suggests that further re-
search, particularly with regard to post-resection utility,
may lead to a change in the decision recommendation
made from this model.
We believe our model is novel in that it incorporates
an anal cancer screening strategy similar to most recent
published guidelines for cervical cancer screening and
follow-up of cervical dysplasia. Most other analyses of
anal cancer screening had attempted to model annual
screening, which in most cases was shown not to be
cost-effective [18, 19–21]. Lazenby et al. utilized a
biennial screening strategy that was shown to be cost-
effective in women with advanced HIV [21]. Our model,
which uses natural history inputs and structural assump-
tions derived from these previously-published studies,
proposes capitalizing on existing screening/followup in-
frastructure, rather than creating a novel program. Even
given the differences between the modeled populations
(otherwise-healthy women with CIN II/III) and the
treatment regimes (reflecting the British Columbia
health care system) between our model and those pub-
lished in the cited literature, we feel that the results from
this exercise support a recommendation that an anal
cancer screening strategy can be adapted to a population
already being screened. Given that our analysis suggests
that women may experience disutility due to screening,
the decision to implement a screening program ought to
consider other factors, such as stakeholder preference
and the health care system’s overall cancer control
strategy.
Conclusions
The addition of anal Pap cytology to regular follow-up
for women with detected CIN II/III lesions was shown
to be 95 % cost-effective at a WTP threshold of $45,500/
LYG. The low incremental effectiveness in terms of LYG
is matched by low incremental costs. The analysis did
not find a difference in terms of quality-adjusted sur-
vival, suggesting that it may not be cost-effective when
QALYs are considered.
This study demonstrates that anal cancer screening,
while not likely to be cost-effective at the level of the
general population, may be useful in populations with a
higher risk of anal cancer who are already regular users
of health care resources. Health care systems should
consider anal screening as a low-cost method of cancer
prevention in women with previously-detected CIN II or
CIN III.
Additional file
Additional file 1: Full Results of Univariate Sensitivity Analysis and
Expected Value of Partial Perfect Information (EVPPI). (DOC 110 kb)
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